USPTO Examiner WORSHAM JESSICA N - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19343371THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSSeptember 2025February 2026Allow510NoNo
19206964COMPOSITION AND METHOD FOR TREATING HEARING LOSSMay 2025September 2025Allow510YesNo
18799983COMPOSITION AND METHOD FOR TREATING HEARING LOSSAugust 2024April 2025Allow811YesNo
18777570METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSAJuly 2024January 2025Allow610YesNo
18760549COMPOSITIONS AND METHODS FOR SUNLESS TANNINGJuly 2024January 2025Allow620YesNo
18665804BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSMay 2024February 2026Allow2100NoNo
18660021NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITIONMay 2024May 2025Allow1220YesNo
18655687COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERYMay 2024June 2025Allow1310YesNo
18620329IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSMarch 2024February 2025Allow1110YesNo
18592160SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONSFebruary 2024March 2025Abandon1310NoNo
18681466SMALL EXTRACELLULAR VESICLES EXPRESSING A DOMINANT NEGATIVE AMPK ALPHA 1 MUTANT FOR USE IN THE TREATMENT OF OBESITYFebruary 2024November 2025Allow2200YesNo
18425556Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerJanuary 2024April 2025Allow1420YesNo
18576171USE OF A VEGETABLE EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF HEART DISEASESJanuary 2024March 2025Allow1420NoNo
18399546Methods for the preparation of biologically active compounds in nanoparticulate formDecember 2023August 2025Abandon2010NoNo
18543854CROSS LINKED SILK-HYALURONIC ACID COMPOSITIONDecember 2023March 2025Abandon1510NoNo
18564822COMPOSITIONS AND METHODS FOR INHIBITING AN INFLAMMATORY RESPONSE AND TREATING INFLAMMATORY DISEASESNovember 2023October 2025Allow2300YesNo
18562492COMPOSITION COMPRISING AN ESTER OF ALPHA-TOCOPHEROL FOR REDUCING THE RISK OF PRETERM BIRTHNovember 2023July 2025Allow1940YesNo
18500489COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAMENovember 2023December 2025Allow2610NoNo
18484519HAIR PROTECTION AND RESTRUCTURING METHOD AND THE RELATED COMPOSITIONSOctober 2023November 2025Allow2600NoNo
18470768METHOD FOR PREPARING A HAEMOSTATIC COMPOSITIONSeptember 2023October 2025Allow2530NoNo
18467953METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACTSeptember 2023November 2024Allow1410YesNo
18467093TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURESeptember 2023July 2025Abandon2320NoNo
18463691ENZYMATICALLY CROSSLINKED COMPOSITIONSSeptember 2023October 2025Abandon2521YesNo
18462346HERNIA REPAIR, BREAST RECONSTRUCTION AND SLING DEVICES CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOFSeptember 2023November 2025Allow2640YesNo
18240488ANTIMICROBIAL BANDAGEAugust 2023December 2024Allow1620YesNo
18365416ELECTROSPUN STRUCTURES HAVING A PHARMACEUTICAL AND METHODS OF MAKING AND USING THE SAMEAugust 2023October 2025Abandon2621NoNo
18351711Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesJuly 2023August 2024Allow1310YesNo
18259175METHOD OF OBTAINING A PHARMACEUTICAL AGENT USED FOR INHIBITING THE PROLIFERATION OF TUMOR CELLSJune 2023January 2026Allow3010YesNo
18257539NANOSYSTEMS BASED ON NANOCOMPOSITES AND NATURAL EXTRACTSJune 2023October 2025Allow2821YesNo
18265903ANTI-OBESITY POTENTIAL OF BISDEMETHOXYCURCUMIN COMPOSITIONSJune 2023February 2025Abandon2010NoNo
18256021FORMULATIONS FOR NON-PARENTERAL ADMINISTRATION OF EXOSOMESJune 2023January 2026Abandon3110NoNo
18200980BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSMay 2023July 2024Abandon1410NoNo
18319948TOPICAL TREATMENT FOR ANIMALSMay 2023August 2024Abandon1501NoNo
18305051METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHYApril 2023May 2024Abandon1310NoNo
18030832NICOTINAMIDE-ENCAPSULATING MICELLES, AND PREGNANCY-INDUCED HYPERTENSION SYNDROME THERAPY COMPOSITION CONTAINING NICOTINAMIDE-ENCAPSULATING MICELLESApril 2023December 2025Abandon3210NoNo
18130484MALLEABLE, CRYOPRESERVED OSTEOGENIC COMPOSITIONS WITH VIABLE CELLSApril 2023August 2025Abandon2841NoNo
18295670PHARMACEUTICAL FORMULATIONApril 2023May 2024Allow1310YesNo
18023233INHIBITORS OF NO PRODUCTIONFebruary 2023February 2026Abandon3510NoNo
18022343PRODUCTS AND METHODS FOR INCREASING NITRIC OXIDE PRODUCTION AND MANAGING OXIDATIVE STRESSFebruary 2023January 2026Abandon3510NoNo
18041449GASTRO-RESISTANT HIGH-STRENGTH FORMULATION CONTAINING POSACONAZOLEFebruary 2023March 2026Allow3710NoNo
18021165NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITIONFebruary 2023May 2025Allow2720YesNo
18006889ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDSJanuary 2023September 2025Allow3110YesNo
18154419Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerJanuary 2023November 2023Allow1010YesNo
17789662BENZOPYRAZOLE COMPOUNDDecember 2022October 2025Allow3910YesNo
18082275Compositions for the Treatment of Dry Eye and Methods of Use ThereofDecember 2022February 2025Abandon2621YesNo
18077390METHOD OF TREATING CANCERDecember 2022November 2025Abandon3610NoNo
18061309PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOFDecember 2022January 2026Allow3710NoNo
18070021Self-Neutralizing Amino Acid Based Cationic CompositionsNovember 2022November 2024Allow2330YesNo
18059270THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOFNovember 2022April 2024Allow1610NoNo
17999233Selenium-Based Compositions and Therapeutic MethodsNovember 2022November 2025Abandon3610NoNo
17984001COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFENNovember 2022February 2024Allow1510YesNo
17997134SELF-TANNING COMPOSITIONS CONTAINING AN AROMATIC SULFONATE AND METHODS THEREOFOctober 2022November 2025Allow3610NoNo
18050021METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACTOctober 2022September 2023Allow1011YesNo
17920850IL4I1 INHIBITORS AND METHODS OF USEOctober 2022July 2025Allow3310NoNo
17966916Composition and method of treatment of elevated ApoE gene expression related health issuesOctober 2022February 2023Allow411YesNo
17966901Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in femalesOctober 2022February 2023Allow411YesNo
18046002Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesOctober 2022June 2023Allow810NoNo
17962753EDIBLE COMPOSITION FOR ALLEVIATING VISUAL FATIGUEOctober 2022July 2025Allow3310NoNo
17917774LOW ENDOTOXIN GELATIN-(METH)ACRYLOYLOctober 2022April 2025Allow3011YesNo
17958322Composition and manufacturing processes of a toxicity free botanical drug for relief from breathing difficultiesOctober 2022February 2026Abandon4120NoNo
17907262COMPOSITIONS FOR TREATMENT OF PSORIASIS OF THE SCALPSeptember 2022October 2025Abandon3710NoNo
17914237NOVEL CERIUM OXIDE NANOCOMPOSITE AND USE THEREOFSeptember 2022July 2025Allow3410NoNo
17948611MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATIONSeptember 2022November 2025Abandon3810NoNo
17942396METHOD OF IDENTIFYING AND TREATING PREMATURE INFANTS AT RISK FOR BPDSeptember 2022January 2024Allow1710YesNo
17910868PARTICLE SIZE CONTROLSeptember 2022November 2025Abandon3810NoNo
17905821METHOD FOR PREPARING POLYDOPAMINE NANOMOTOR USING UREASE, AND USE OF SAMESeptember 2022January 2026Allow4111NoNo
17823020COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDESAugust 2022March 2024Allow1910NoNo
17904833A CONTROLLED DRUG RELEASE SYSTEM OF PHOTORESPONSIVE NANOCARRIERS, METHODS OF MAKING AND USING THEREOFAugust 2022August 2025Allow3500YesNo
17878998Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and Tetrahydrocannabinol (THC)August 2022August 2025Allow3720YesNo
17812479Lapatinib particles and uses thereofJuly 2022January 2024Allow1821YesNo
17758308GOLD CLUSTERS (AuCs), COMPOSITION AND METHOD FOR TREATMENT OF LIVER CIRRHOSISJuly 2022February 2026Allow4321YesNo
17787206COSMETIC COMPOSITION HAVING GLOSS AND LASTING PROPERTIESJune 2022March 2026Allow4530NoNo
17784575MINERAL SUPPLEMENTS FOR RUMINANT NUTRITIONJune 2022March 2025Allow3321NoNo
17756231NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASESMay 2022January 2026Allow4420YesNo
17745923Pouches Comprising Oral Care Active AgentsMay 2022April 2024Abandon2330NoNo
17738803THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSMay 2022April 2023Allow1110NoNo
17774445GASTRIC RESIDENCE SYSTEMS HAVING ARMS WITH CONTROLLED STIFFNESS FOR IMPROVED GASTRIC RESIDENCEMay 2022March 2026Abandon4601NoNo
17719912ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USE IN A DISPENSERApril 2022September 2024Abandon2941YesNo
17713069CROSS LINKED SILK-HYALURONIC ACID COMPOSITIONApril 2022December 2023Abandon2120NoNo
17703955COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR POULTRY OVARIAN HEALTHMarch 2022March 2024Allow2430NoNo
17685830PHARMACEUTICAL COMPOSITIONS OF PIMOBENDANMarch 2022September 2024Allow3140YesNo
17680970COMPOSITION FOR TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONSFebruary 2022August 2024Allow2910NoNo
17627878Porous Self-Healing Polymer Matrix For Encapsulation Of Active Macromolecules And MethodsJanuary 2022December 2025Allow4711YesNo
17628191ANTI-COCCIDIAL PHYTOGENIC FORMULATIONSJanuary 2022May 2025Abandon4020NoNo
17570194STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAMEJanuary 2022July 2025Allow4330NoNo
17596647PROTEIN-MODIFIED PLGA MICROSPHERE AND TISSUE-ENGINEERED NERVE CONSTRUCTED THEREWITHDecember 2021August 2023Allow2020YesNo
17644069CENTRAL NERVOUS SYSTEM HEALTH SUPPLEMENTDecember 2021May 2025Allow4110NoNo
17546640EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITYDecember 2021May 2023Allow1710YesNo
17540695KETAMINE TRANSDERMAL DELIVERY SYSTEMDecember 2021February 2024Abandon2610NoNo
17595908DELAYED DISINTEGRATION-TYPE CAPSULE AND METHOD FOR PRODUCING SAMENovember 2021September 2025Allow4621YesNo
17532874BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSNovember 2021March 2023Allow1510YesNo
17612100CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAINNovember 2021May 2025Abandon4201NoNo
17525298COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFENNovember 2021August 2022Allow920NoNo
17454320IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSNovember 2021March 2024Allow2810YesNo
17609535A PHARMACEUTICAL HERBO-MINERAL METALLIC COMPOSITION AND A PROCESS FOR PREPARATION THEREOFNovember 2021August 2025Allow4621YesNo
17595019ANTI-CANCER GOLD COMPOUNDSNovember 2021September 2024Allow3410NoNo
17604615GRANULAR PRODUCT BASED ON ARGININEOctober 2021November 2025Allow4920NoNo
17604133NON-AQUEOUS DRIFT CONTROL SUSPENSIONSOctober 2021July 2025Allow4521YesNo
17499648METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLSOctober 2021April 2024Abandon3001NoNo
17497819HIGHLY TRANSPARENT WATER CONTINUOUS DENSE NANOLIPID FLUID (DNLF) DISPERSIONS AND METHOD OF PREPARATION USING A TWIN SCREW EXTRUDEROctober 2021December 2024Allow3831YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WORSHAM, JESSICA N.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
12
(63.2%)
Examiner Reversed
7
(36.8%)
Reversal Percentile
58.1%
Higher than average

What This Means

With a 36.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
111
Allowed After Appeal Filing
29
(26.1%)
Not Allowed After Appeal Filing
82
(73.9%)
Filing Benefit Percentile
37.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WORSHAM, JESSICA N - Prosecution Strategy Guide

Executive Summary

Examiner WORSHAM, JESSICA N works in Art Unit 1615 and has examined 701 patent applications in our dataset. With an allowance rate of 55.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner WORSHAM, JESSICA N's allowance rate of 55.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WORSHAM, JESSICA N receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WORSHAM, JESSICA N is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.6% benefit to allowance rate for applications examined by WORSHAM, JESSICA N. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.4% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 81% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.9% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 56.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.3% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.